Chronic spontaneous urticaria

18 trials 5 recruiting MedDRA PT
18 Registered trials
5 Recruiting
12 Unique sponsors
14 Unique IMPs
16 Commercial trials
Drug classes (ATC)
— ATC code not specified 11
N Neurology/Psychiatry (ATC N) 1
C Cardiology (ATC C) 3
R Respiratory (ATC R) 1
J Anti-infectives (ATC J) 1
L Oncology (ATC L) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 5 substances
JAK inhibitor 2 substances
Monoclonal antibody (immune) 2 substances
Receptor fusion protein 1 substance
Monoclonal antibody (immune, humanized) 1 substance
BTK inhibitor 1 substance
Vaccine 1 substance
Monoclonal antibody (humanized) 1 substance
Phase III: 8 Phase II: 8 Phase I/II: 1 Phase I (Other): 1

Filter these 18 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 18 trials

Phase III

8 trials
  • Celldex Therapeutics Inc. Commercial
    BARZOLVOLIMAB; EPINEPHRINE
    2024-513208-32-00 11 countries 2024 n=521
    Ended
  • Celldex Therapeutics Inc. Commercial
    BARZOLVOLIMAB; EPINEPHRINE
    2024-513210-36-00 10 countries 2025 n=528
    Ended
  • Celldex Therapeutics Inc. Commercial
    BARZOLVOLIMAB; EPINEPHRINE
    2025-522878-36-00 16 countries 2026 n=438
    Recruiting
  • Curateq Biologics Private Limited Commercial
    OMALIZUMAB
    2024-514764-72-00 6 countries 2023 n=474
    Ended
  • Novartis Pharma AG Commercial
    REMIBRUTINIB
    2022-502159-78-00 5 countries 2023 n=27
    Recruiting
  • Novartis Pharma AG Commercial
    REMIBRUTINIB
    2022-502161-19-00 10 countries 2024 n=218
    Ended
  • Novartis Pharma AG Commercial
    REMIBRUTINIB
    2024-510818-33-00 10 countries 2023 n=200
    Ended
  • Novartis Pharma AG Commercial
    REMIBRUTINIB
    2025-524078-40-00 6 countries n=154
    Pending

Phase II

8 trials
  • Escient Pharmaceuticals Inc. Commercial
    EP262
    2023-504799-94-00 4 countries 2024 n=44
    Ended
  • Evommune Inc. Commercial
    EVO756 POTASSIUM
    2024-518786-10-01 6 countries n=63
    Pending
  • Incyte Corp. Commercial
    POVORCITINIB
    2022-503062-72-00 2 countries 2023 n=66
    Ended
  • InflaRx GmbH Commercial
    INF904
    2024-515615-22-00 4 countries 2025 n=60
    Ended
  • Pfizer Inc. Commercial
    RITLECITINIB TOSILATE
    2025-522642-44-00 4 countries 2026 n=46
    Recruiting
  • Yuhan Corp. Commercial
    LESIGERCEPT
    2025-524006-14-00 2 countries 2026 n=46
    Recruiting
  • Fraunhofer Institute For Translational Medicine And Pharmacology ITMP Academic
    NEISSERIA MENINGITIDIS, SEROGROUP C, POLYSACCHARIDE, CONJUGATED TO TETANUS TOXOID, NEISSERIA MENINGITIDIS GROUP A POLYSACCHARIDE CONJUGATED TO TETANUS TOXOID CARRIER PROTEIN, NEISSERIA MENINGITIDIS GROUP W-135 POLYSACCHARIDE CONJUGATED TO TETANUS TOXOID CARRIER PROTEIN, NEISSERIA MENINGITIDIS GROUP Y POLYSACCHARIDE CONJUGATED TO TETANUS TOXOID CARRIER PROTEIN; RECOMBINANT NEISSERIA MENINGITIDIS GROUP B NHBA FUSION PROTEIN PRODUCED IN E. COLI CELLS BY RECOMBINANT DNA TECHNOLOGY ADSORBED ON ALUMINIUM HYDROXIDE, RECOMBINANT NEISSERIA MENINGITIDIS GROUP B NADA PROTEIN PRODUCED IN E. COLI CELLS BY RECOMBINANT DNA TECHNOLOGY ADSORBED ON ALUMINIUM HYDROXIDE, RECOMBINANT NEISSERIA MENINGITIDIS GROUP B FHBP FUSION PROTEIN PRODUCED IN E. COLI CELLS BY RECOMBINANT DNA TECHNOLOGY ADSORBED ON ALUMINIUM HYDROXIDE, OUTER MEMBRANE VESICLES (OMV) FROM NEISSERIA MENINGITIDIS GROUP B STRAIN NZ98/254 MEASURED AS AMOUNT OF TOTAL PROTEIN CONTAINING THE PORA P1.4 ADSORBED ON ALUMINIUM HYDROXIDE
    2024-512386-14-00 1 country n=24
    Ended
  • Philipps-Universitaet Marburg Academic
    TILDRAKIZUMAB
    2024-513155-32-00 1 country 2026 n=18
    Recruiting

Phase I/II

1 trial
  • Jasper Therapeutics Inc. Commercial
    BRIQUILIMAB
    2023-505446-25-00 1 country 2024 n=31
    Ended

Phase I (Other)

1 trial
  • Novartis Pharma AG Commercial
    IMP not specified
    2023-506760-13-00 1 country 2023 n=16
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Novartis Pharma AG Commercial 5 Phase I (Other), Phase III 1
Celldex Therapeutics Inc. Commercial 3 Phase III 1
Escient Pharmaceuticals Inc. Commercial 1 Phase II 0
Evommune Inc. Commercial 1 Phase II 0
Incyte Corp. Commercial 1 Phase II 0
InflaRx GmbH Commercial 1 Phase II 0
Pfizer Inc. Commercial 1 Phase II 1
Yuhan Corp. Commercial 1 Phase II 1
Curateq Biologics Private Limited Commercial 1 Phase III 0
Jasper Therapeutics Inc. Commercial 1 Phase I/II 0
Fraunhofer Institute For Translational Medicine And Pharmacology ITMP Academic 1 Phase II 0
Philipps-Universitaet Marburg Academic 1 Phase II 1
New trials by year
2023
5
2024
4
2025
2
2026
4
← All indication landscapes